Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762850 · ClinicalTrials.gov registry record · Phase 3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
A Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
- 20
- Study locations
NCT03762850: Active Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
NCT03762850 is a Phase 3 study of Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Travere Therapeutics. The registered enrollment target is 406 participants, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03762850, a Phase 3 study of Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Travere Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Primary Outcome
24-hour urine sample was collected for analysis of UP/C via a mixed-model repeated-measures (MMRM) analysis. Missing responses were imputed prior to analysis using multiple imputation. Change from Baseline during the double-blind period in UP/C on the log scale was the dependent variable. Log Baseline UP/C was included as a covariate along with fixed effects for randomized treatment, time (ie, nominal visit in weeks), randomized treatment-by-time interaction, and randomization strata with partic
Conditions Studied
Interventions
- DRUG Dapagliflozin
- DRUG sparsentan
- DRUG irbesartan
Study Locations (20)
California
- Travere Investigational Site - Glendale
- Travere Investigational Site - Montebello
- Travere Investigational Site - Northridge
- Travere Investigational Site - San Diego
- Travere Investigational Site - San Diego
- Travere Investigational Site - Stanford
Florida
- Travere Investigational Site - Coral Springs
- Travere Investigational Site - Hollywood
- Travere Investigational Site - Miami
- Travere Investigational Site - Miami
- Travere Investigational Site - Winter Park
Alabama
- Travere Investigational Site - Birmingham
- Travere Investigational Site - Homewood
Colorado
- Travere Investigational Site - Denver
Georgia
- Travere Investigational Site - Lawrenceville
Idaho
- Travere Investigational Site - Nampa
Illinois
- Travere Investigational Site - Hinsdale
Indiana
- Travere Investigational Site - Muncie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
What the registry record for NCT03762850 still lists
NCT03762850 is an interventional study that assigns participants to a tested intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 3 interventions - of which Dapagliflozin is the first listed.
NCT03762850 names 20 study sites across 10 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03762850 about?
NCT03762850 is a clinical study titled "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy". To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
What is the current status of trial NCT03762850?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2018-12-11. Estimated completion is 2026-07.
What conditions does trial NCT03762850 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.
What interventions are being tested in trial NCT03762850?
The interventions under investigation include: Dapagliflozin (DRUG), sparsentan (DRUG), irbesartan (DRUG).
Who is sponsoring clinical trial NCT03762850?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03762850 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03762850's enrollment target sits among peer trials
406 5th of 13 higher than 9 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI